Prestige Biopharma’s New Vaccine Production Centre, South Korea
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X
Projects

Prestige Biopharma’s New Vaccine Production Centre, Osong, South Korea

Prestige Biopharma (PBP), a Singapore-based biopharmaceutical company, is building a global-scale vaccine manufacturing centre in Osong, South Korea.

Project Type

Vaccine production centre

Location

Osong, South Korea

Owner

Prestige Biopharma

Area

8,500m²

Expand

Prestige Biopharma (PBP), a Singapore-based biopharmaceutical company, is building a global-scale vaccine manufacturing centre in Osong, South Korea.

The company is focused on expanding its business portfolio to include the production of vaccines and therapeutics to deal with ongoing and possible viral pandemics in the future. The design, development and implementation of the vaccine centre, which is part of the business expansion plans, will help meet the global demand for vaccines.

Construction of the vaccine development and production centre began with a ground-breaking ceremony held in March 2021. In addition to the production of Covid-19 vaccines, the facility will be engaged in the development of vaccines for infectious diseases in the future.

The centre is scheduled to be completed by the end of 2021, with test operations set to start in August 2021.

Prestige Biopharma’s Vaccine Production Centre details

Spanning 8,500m², PBP’s manufacturing facility is being built within the Campus II site of its subsidiary, Prestige Biologics, in Osong.

The vaccine centre will have up to 100,000l of production capacity upon completion.
It will include 50 units of 2,000l single-use bioreactors equipped with seed trains and downstream purification capabilities.

Using Prestige Biologics’ customised engineering technology, the vaccine centre will be built to be applied to different manufacturing processes and optimise performance.

A smart factory construction technique, ALITA Smart BioFactory, is being incorporated into the centre’s construction. A patented technology of Prestige Biologics, Alita Smart BioFactory is an artificial intelligence (AI) based system that can minimise human errors during the biomanufacturing process.

Designed to improve production efficiency, the futuristic engineering system will facilitate mass vaccine production within a short time.

The smart factory single-use system will also allow rapid and convenient changeover to improve manufacturing efficiency while catering to various products and processes.

The vaccine centre intends to begin full production of the Sputnik V Covid-19 vaccine in September 2021.

Details of Prestige Biologics’ existing campuses

With a state-of-the-art good manufacturing practice (GMP) certified biopharmaceutical manufacturing facility, Prestige Biologics is a contract development and manufacturing organisation (CDMO) focused on antibody drug and biopharmaceutical production.

Located at the Osong Advanced Medical Complex in South Korea’s Chungcheongbuk-do province, Prestige Biologics was established in 2015. Construction of the first campus started in 2017 and was completed in June 2018.

The first campus, with a total production capacity of 6,000l, extends across a land area of 10,560m² and features a single-use production method.

The company was given GMP certification by the Korean Food and Drug Administration in April 2019.

The second campus (Campus II) is currently under construction and will be completed in two stages. Scheduled to be completed by December 2021, the first phase will have a production capacity of 28,000l. The second phase will add 70,000l, increasing the total production capacity to 98,000l.

Prestige biologics will have a total production scale of 104,000l, following the completion of the second factory in 2022.

Marketing commentary on Prestige Biopharma

PBP is a biopharmaceutical company specialising in the discovery and development of innovative biologics and biosimilars.

With a strong pharmaceutical portfolio in the Asia-Pacific region, PBP’s research and development team primarily focuses on oncology and immune disorders as well as the development of new and similar antibody therapeutics for pancreatic cancer, arthritis and solid tumours.

PBP successfully completed phase I and III clinical trials on Herceptin biosimilar, HD201, a drug for adult patients with HER2-overexpressing breast cancer as well as HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Market launch is expected in 2021.

Prestige Biopharma is planning to develop new drug candidates for immunology, oncology and degenerative and metabolic disorders.

The company’s existing biosimilar pipeline includes Avastin Biosimilar (HD204), Herceptin Biosimilar (HD201), Denosumab Biosimilar (PBP1601), Humira Adalimumab (PBP1502), Aflibercept Biosimilar (PBP1602) and Eculizumab Biosimilar (PBP1603).

Related Projects